Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

How I Treat Plasma Cell Leukemia.

Blood·2026
Same author

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Blood cancer journal·2026
Same author

The post-BCMA playbook: RD118 GPRC5D CAR T cells for myeloma.

Blood·2026
Same author

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.

Blood cancer journal·2026

Related Experiment Video

Updated: Jun 28, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K

Targeting GPRC5D in multiple myeloma.

Shatha Elemian1, Samer Al Hadidi2

  • 1Department of Internal Medicine, Saint Michael's Medical Center, Newark, NJ, USA.

Expert Review of Anticancer Therapy
|April 12, 2024
PubMed
Summary

New therapies targeting G protein-coupled receptor, class C group 5 member D (GPRC5D) show promise for multiple myeloma (MM). Talquetamab, an FDA-approved bispecific antibody, offers high response rates in relapsed or refractory MM patients.

Keywords:
CAR-TGPRC5DTalquetamabadverse eventsbispecific antibodiesmultiple myeloma

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.9K

Related Experiment Videos

Last Updated: Jun 28, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.8K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.9K

Area of Science:

  • Oncology
  • Hematology
  • Immunotherapy

Background:

  • Multiple myeloma (MM) prognosis improves with therapies like IMiDs, PIs, and anti-CD38 antibodies.
  • Relapses and treatment resistance remain challenges in MM management.
  • Novel agents like CAR T-cell therapy and BCMA-targeting BsAbs show efficacy in advanced MM.

Purpose of the Study:

  • To review the efficacy and safety of GPRC5D-targeting CAR-T and BsAbs in MM.
  • To focus on talquetamab, the first FDA-approved GPRC5D-targeting BsAb.
  • To discuss ongoing trials of talquetamab in combination therapies.

Main Methods:

  • Review of clinical trial data for GPRC5D-targeted therapies in MM.
  • Analysis of talquetamab's efficacy and safety profile.
  • Examination of combination strategies involving talquetamab.

Main Results:

  • GPRC5D is a promising target in MM, with early trials showing high response rates.
  • Talquetamab demonstrates significant response rates in relapsed/refractory MM.
  • Talquetamab presents a unique side effect profile requiring careful management.

Conclusions:

  • GPRC5D-targeted therapies, including talquetamab, represent a significant advancement in MM treatment.
  • Talquetamab's potential use in combination with other agents warrants further investigation.
  • These novel therapies offer new hope for patients with limited treatment options in MM.